Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06188195 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Study sites: 0 to 1
    v3
  2. Start date: Jan 1, 2024 to Feb 1, 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
1. A predictive model for NARDS was established based on perinatal risk factors. Multivariate Logistic regression analysis was used to screen the independent prenatal risk factors for NARDS. A Logistic regression model was constructed using the above independent risk factors and quantified in a nomogram to construct a visualization model for prenatal prediction of NARDS. 2. The role of ACS in the prevention and treatment of ARDS in near-term/full-term infants. For neonates with a probability greater than 80% in the prediction model of ARDS, at least one ACS was given before the termination of pregnancy. The GC level of cord blood (taken at birth) and the mRNA levels of α-ENaC, Na-K-atpase and SGK1 in nasal epithelium were measured within 2 hours and 1 day after birth in the ACS intervention group and the control group. The occurrence and severity of pulmonary edema, the occurrence and severity of ARDS, and the mortality rate of NARDS were evaluated by lung ultrasound. The indexes of the two groups were compared horizontally and longitudinally.
Trial Details
NCT Number NCT06188195
Lead Sponsor The Second Affiliated Hospital of Chongqing Medical University
Collaborators: University-Town Hospital of Chongqing Medical University, Children's Hospital of Chongqing Medical University, Chongqing Medical Center for Women and Children
Conditions
(from sponsor)		 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome, Acute
Related terms Respiratory Distress Syndrome
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov